|Day Low/High||3.12 / 3.56|
|52 Wk Low/High||3.52 / 91.00|
Collaboration Aimed Towards Reaching a Cure for Hepatitis B Virus (HBV) Infection
The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.